Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07MNI
|
|||
| Drug Name |
PMID25666693-Compound-127
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Patented | [1] | |
| Inflammatory pain [ICD-11: MG30.42; ICD-10: R52, G89] | Patented | [1] | ||
| Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
| Osteoarthritis pain [ICD-11: MG30.31] | Patented | [1] | ||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H22FN5O
|
|||
| Canonical SMILES |
C1CCN2C(=NC3=C2C=CC(=C3)NC(=O)C4=CC5=C(N4CC6=CC=NC=C6)C=CC(=C5)F)C1
|
|||
| InChI |
1S/C26H22FN5O/c27-19-4-6-22-18(13-19)14-24(32(22)16-17-8-10-28-11-9-17)26(33)29-20-5-7-23-21(15-20)30-25-3-1-2-12-31(23)25/h4-11,13-15H,1-3,12,16H2,(H,29,33)
|
|||
| InChIKey |
NFRFMCDNQXJWRI-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Transient receptor potential cation channel V1 (TRPV1) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
| Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.